Lunit Inc. (KOSDAQ:328130)

Market Cap	1.20T
Revenue (ttm)	76.69B
Net Income (ttm)	-88.24B
Shares Out	29.26M
EPS (ttm)	-3,513.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,650
Average Volume	302,348
Open	41,300
Previous Close	40,850
Day's Range	40,400 - 42,100
52-Week Range	34,150 - 77,100
Beta	1.34
RSI	53.05
Earnings Date	Feb 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a...

• Industry: Software - Application
• Sector: Technology
• Founded: 2013
• Employees: 307
• Stock Exchange: KOSDAQ
• Ticker Symbol: 328130

Financial Performance

In 2024, Lunit's revenue was 54.18 billion, an increase of 116.03% compared to the previous year's 25.08 billion. Losses were -82.42 billion, 124.0% more than in 2023.